Seoul Court Overturns Health Ministry's 14-Percent Price Cut On Novartis' Glivec
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Seoul's Administrative Court ruled in favor of Novartis and suspended the Korean health ministry's plan to cut the price of the Swiss-based company's leukemia drug Glivec (imatinib) by 14 percent beginning Sept. 15